Boutique Diagnostics

Digital Health Market Access Consulting Firm

Digital Health Solutions

Diagnostics reimbursement

Performance-based Risk-sharing Agreements in Diagnostics: Part 2, Europe

Performance-based Risk-sharing Agreements in Diagnostics: Part 2, Europe

In our second part in this mini-series, today we look at the landscape, trends and challenges in Performance-Based Risk Sharing Agreements in Europe.

Performance-based Risk-sharing Agreements in Diagnostics: Part 1 USA

Performance-based Risk-sharing Agreements in Diagnostics: Part 1 USA

We look at the first systematic review of an ever-evolving diagnostic access pathway, performance-based risk-sharing agreements, in the United States. In our next blogpost, we will review the same trends in diagnostic patient access in Europe.

Are you newly joining diagnostics access? Check out this short video how to be successful in the job.

Are you newly joining diagnostics access? Check out this short video how to be successful in the job.

Pricing diagnostics with 4 methods. Which is the most powerful? - Watch the short video

Pricing diagnostics with 4 methods. Which is the most powerful? - Watch the short video

Number #1 access mistake diagnostics start-ups make. And how to avoid it?

Number #1 access mistake diagnostics start-ups make. And how to avoid it?

At Centivis we have the privilege to serve global, specialized, and start-up diagnostics developers. Depending on the size and maturity of the businesses, unique access challenges arise. We are thrilled to support start-ups / scale-ups since they are the engine of innovation in the field. What is the Nr. #1 access mistake diagnostics start-ups make. And how to avoid it?

Securing coverage for digital diagnostics | presentation for Zurich University of Applied Sciences

Securing coverage for digital diagnostics | presentation for Zurich University of Applied Sciences

Very recently Anastasios Gkiokas shared our view on “Securing coverage for digital diagnostic solutions”. Read the blog entry for the key highlights of his talk.

Germany’s Digital Healthcare Act – A glimpse on the first applicants

Germany’s Digital Healthcare Act – A glimpse on the first applicants

Digital Healthcare Act (DiGAV) aims to create a solid reimbursement pathway for digital health solutions in the German healthcare market. BfArM, the body that determines which solution will be enlisted in the DiGA registry, opened its application portal in May, and it is expected to publish the first application results later this month.

Meanwhile, the umbrella association for digital healthcare acts (Spitzenverband Digitale Gesundheitsversorgung) has disclosed some of the first companies that applied for inclusion in the DiGA registry.

How does the UK's NICE evaluate diagnostic technologies? 1-pager summary

How does the UK's NICE evaluate diagnostic technologies? 1-pager summary

How does the UK's NICE evaluate diagnostic technologies? 1-pager summary

Download Insights – Prostate Cancer Diagnostics Solutions

Download Insights – Prostate Cancer Diagnostics Solutions

Prostate cancer is the 2nd most commonly diagnosed cancer amongst men. Many men also go through invasive biopsies that yield negative results.

What tests are used to diagnose prostate cancer, minimize invasive biopsies, and improve prognosis? Check out our short report.

Spotlight on Germany’s Digital Healthcare Reimbursement Pathway

Spotlight on Germany’s Digital Healthcare Reimbursement Pathway

Germany’s digital healthcare market is about to open up, thanks to the Digital Healthcare Act (DiGAV), which puts in place a solid reimbursement pathway for digital health solutions. In this blog post, we answer some frequently asked questions, relevant to market access, with insights from recently published documents/conferences on the topic.

Switzerland – New Highly Specialized Rare Disease Diagnostic Tests Reimbursed

Switzerland – New Highly Specialized Rare Disease Diagnostic Tests Reimbursed

Switzerland regularly updates the Analysenliste (AL), a comprehensive list of diagnostic tests that are covered by compulsory health insurance. As of April 2020, among others, the following new rare disease genetic tests will be added to the list: